Celgene Stock Price, News & Analysis (NASDAQ:CELG)

$108.23 -0.81 (-0.74 %)
(As of 12/13/2017 03:57 PM ET)
Previous Close$109.04
Today's Range$107.33 - $109.94
52-Week Range$94.55 - $147.17
Volume4.23 million shs
Average Volume4.78 million shs
Market Capitalization$85.85 billion
P/E Ratio16.88
Dividend YieldN/A
Beta1.77

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CELG
CUSIP15102010
Phone+1-908-6739000

Debt

Debt-to-Equity Ratio1.31%
Current Ratio3.65%
Quick Ratio3.52%

Price-To-Earnings

Trailing P/E Ratio16.88
Forward P/E Ratio16.23
P/E Growth0.83

Sales & Book Value

Annual Sales$11.23 billion
Price / Sales7.59
Cash Flow$6.04 per share
Price / Cash17.93
Book Value$8.51 per share
Price / Book12.72

Profitability

Trailing EPS$4.24
Net Income$2.00 billion
Net Margins27.36%
Return on Equity63.80%
Return on Assets17.45%

Miscellaneous

Employees7,132
Outstanding Shares787,320,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) posted its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The biopharmaceutical company earned $3.29 billion during the quarter, compared to analysts' expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS. View Celgene's Earnings History.

When will Celgene make its next earnings announcement?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY17 earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $7.30-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.31. The company issued revenue guidance of $13 billion, compared to the consensus revenue estimate of $13.23 billion.

Where is Celgene's stock going? Where will Celgene's stock price be in 2017?

31 brokerages have issued 12 month price objectives for Celgene's stock. Their forecasts range from $91.00 to $166.00. On average, they anticipate Celgene's share price to reach $136.78 in the next year. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • 1. Cann analysts commented, "We conducted a physician survey to evaluate the current treatment preferences and satisfaction with available therapies, along with expectations for therapies in clinical development. Our report (published 11/21/17), Multiple Sclerosis Survey: Unmet Need Persists Despite Several Approved Treatment Options, concluded that there is a meaningful unmet need in MS treatment and a high level of interest in Ozanimod if FDA-approved. We conclude that approximately 80% of the neurologists surveyed are unsatisfied with the therapies available to them. The survey showed that 40.4% of patients are being treated with oral therapy. The surveyed neurologists replied that they would, on average, put 23.8% of their patients on a newly approved therapy they had selected from the survey." (11/22/2017)
  • 2. Cantor Fitzgerald analysts commented, "SUNBEAM and RADIANCE Shine Bright. Both these studies (one year and two years, respectively), in our view, show ozanimod to be a competitive agent in the field, with statistically significant reductions in annualized relapse rate for both time intervals: 48% at one year and 38% at two years for the 1 mg dose." (10/30/2017)
  • 3. BTIG Research analysts commented, "After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn." (10/22/2017)
  • 4. According to Zacks Investment Research, "Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure." (10/18/2017)

Are investors shorting Celgene?

Celgene saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 12,302,389 shares, an increase of 37.9% from the October 31st total of 8,920,850 shares. Based on an average daily volume of 7,542,396 shares, the short-interest ratio is presently 1.6 days. Currently, 1.6% of the company's shares are sold short.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board (Age 62)
  • Scott A. Smith, President, Chief Operating Officer (Age 55)
  • Mark J. Alles, Chief Executive Officer, Director (Age 58)
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
  • Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
  • Michael F. Pehl, President, Hematology & Oncology (Age 52)
  • Rupert J Vessey, President - Research and Early Development (Age 52)
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
  • Michael D. Casey, Lead Independent Director (Age 71)
  • Michael W. Bonney, Director (Age 59)

Who owns Celgene stock?

Celgene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (1.90%), Edgewood Management LLC (1.34%), Ameriprise Financial Inc. (1.21%), Bank of New York Mellon Corp (1.21%), Janus Henderson Group PLC (1.20%) and American Century Companies Inc. (0.83%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Jackson Square Partners LLC, Ameriprise Financial Inc., ING Groep NV, Bank of New York Mellon Corp, USS Investment Management Ltd, Macquarie Group Ltd. and California State Teachers Retirement System. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, Patten Group Inc., Schroder Investment Management Group, Investec Asset Management LTD, Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P. and KBC Group NV. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of Celgene stock can currently be purchased for approximately $109.04.

How big of a company is Celgene?

Celgene has a market capitalization of $85.85 billion and generates $11.23 billion in revenue each year. The biopharmaceutical company earns $2.00 billion in net income (profit) each year or $4.24 on an earnings per share basis. Celgene employs 7,132 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 Morris Ave, SUMMIT, NJ 07901-3915, United States. The biopharmaceutical company can be reached via phone at +1-908-6739000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  1,637 (Vote Outperform)
Underperform Votes:  476 (Vote Underperform)
Total Votes:  2,113
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.822.77
Ratings Breakdown: 1 Sell Rating(s)
11 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
22 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
24 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $137.30$140.20$148.43$139.90
Price Target Upside: 27.07% upside40.15% upside5.61% upside16.00% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017Leerink SwannReiterated RatingBuy$120.00LowView Rating Details
12/12/2017Credit Suisse GroupSet Price TargetBuy$128.00LowView Rating Details
12/12/2017Deutsche BankInitiated CoverageHold$114.00LowView Rating Details
12/10/2017Piper Jaffray CompaniesReiterated RatingHoldHighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetHold$112.00HighView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral -> OverweightHighView Rating Details
11/22/2017CannReiterated RatingBuy$166.00N/AView Rating Details
11/17/2017BMO Capital MarketsBoost Price TargetOutperform$148.00 -> $155.00N/AView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
11/16/2017OppenheimerSet Price TargetBuy$166.00N/AView Rating Details
11/3/2017MizuhoReiterated RatingBuyN/AView Rating Details
10/27/2017J P Morgan Chase & CoSet Price TargetBuy$123.00N/AView Rating Details
10/27/2017BarclaysReiterated RatingEqual Weight -> Equal Weight$135.00 -> $105.00N/AView Rating Details
10/27/2017CitigroupLower Price TargetNeutral$140.00 -> $102.00N/AView Rating Details
10/27/2017SunTrust BanksLower Price TargetBuy -> Buy$156.00 -> $127.00N/AView Rating Details
10/27/2017Royal Bank of CanadaLower Price TargetTop Pick$166.00 -> $148.00N/AView Rating Details
10/27/2017Goldman Sachs GroupReiterated RatingSell$116.00 -> $91.00N/AView Rating Details
10/27/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/AView Rating Details
10/26/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy -> Buy$160.00N/AView Rating Details
10/22/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/20/2017Stifel NicolausLower Price TargetBuy$155.00 -> $149.00N/AView Rating Details
10/17/2017Sanford C. BernsteinInitiated CoverageOutperform$162.00N/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/13/2017Bank of AmericaReiterated RatingBuyLowView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond James FinancialReiterated RatingBuyN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$1.94N/AView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.42 billion$3.29 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Celgene (NASDAQ:CELG) Earnings Estimates

2017 EPS Consensus Estimate: $6.61
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20173$1.61$1.68$1.64
Q3 20173$1.68$1.81$1.73
Q4 20173$1.72$1.84$1.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene (NASDAQ:CELG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 80.16%
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.03View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.00View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.50View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.12View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.00View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.00View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.00View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.80View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.50View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
Celgene (CELG) Downgraded by Vetr to "Buy"Celgene (CELG) Downgraded by Vetr to "Buy"
www.americanbankingnews.com - December 13 at 1:00 AM
Deutsche Bank Begins Coverage on Celgene (CELG)Deutsche Bank Begins Coverage on Celgene (CELG)
www.americanbankingnews.com - December 12 at 10:06 PM
bluebird bio Stock Soars on Unprecedented Blood Cancer Study ... - Yahoo Newsbluebird bio Stock Soars on Unprecedented Blood Cancer Study ... - Yahoo News
finance.yahoo.com - December 12 at 5:24 PM
Bluebird's Shares Jump on Strong Data for CAR-T TherapyBluebird's Shares Jump on Strong Data for CAR-T Therapy
finance.yahoo.com - December 12 at 5:24 PM
US STOCKS-Wall St ticks higher as New York explosion worries wane - ReutersUS STOCKS-Wall St ticks higher as New York explosion worries wane - Reuters
www.reuters.com - December 12 at 10:18 AM
Wall St rises with help from technology, energy sectors - NasdaqWall St rises with help from technology, energy sectors - Nasdaq
www.nasdaq.com - December 12 at 10:18 AM
Wall Street Ends Higher With Help From Tech, Energy - New York TimesWall Street Ends Higher With Help From Tech, Energy - New York Times
www.nytimes.com - December 11 at 5:12 PM
US STOCKS-Wall St to open higher, futures recover after explosion scare - ReutersUS STOCKS-Wall St to open higher, futures recover after explosion scare - Reuters
www.reuters.com - December 11 at 5:12 PM
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results - Motley Foolbluebird bio Stock Soars on Unprecedented Blood Cancer Study Results - Motley Fool
www.fool.com - December 11 at 5:12 PM
Biotech Stocks Soar On Trial Data At Hematology ConferenceBiotech Stocks Soar On Trial Data At Hematology Conference
finance.yahoo.com - December 11 at 5:12 PM
4 Stocks Move to Start the Week4 Stocks Move to Start the Week
finance.yahoo.com - December 11 at 5:12 PM
Fewer Negatives Lift Ranking of Celgene (CELG) to HoldFewer Negatives Lift Ranking of Celgene (CELG) to Hold
investorplace.com - December 11 at 2:38 PM
Celgene CEO: New therapies for a certain type of cancer boost survival rates 10-foldCelgene CEO: New therapies for a certain type of cancer boost survival rates 10-fold
www.cnbc.com - December 11 at 2:31 PM
Celgene (CELG) Given "Hold" Rating at Piper Jaffray CompaniesCelgene (CELG) Given "Hold" Rating at Piper Jaffray Companies
www.americanbankingnews.com - December 11 at 1:26 PM
Juno Therapeutics, Celgene Release Additional Data From TRANSCEND TrialJuno Therapeutics, Celgene Release Additional Data From TRANSCEND Trial
www.nasdaq.com - December 11 at 10:36 AM
Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin LymphomaJuno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
finance.yahoo.com - December 11 at 10:36 AM
Bluebird, Celgene Myeloma Therapy Appears to Improve in TimeBluebird, Celgene Myeloma Therapy Appears to Improve in Time
finance.yahoo.com - December 11 at 10:36 AM
Highlights from ASH Sent bluebird Bio Inc (BLUE) Shares Skyrocketing; J.P. Morgan CheersHighlights from ASH Sent bluebird Bio Inc (BLUE) Shares Skyrocketing; J.P. Morgan Cheers
finance.yahoo.com - December 11 at 10:36 AM
Celgene takes new approach to multiple myeloma treatmentCelgene takes new approach to multiple myeloma treatment
finance.yahoo.com - December 11 at 10:36 AM
Celgene (CELG) Given a $112.00 Price Target at Cantor FitzgeraldCelgene (CELG) Given a $112.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 11 at 9:46 AM
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Resultsbluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
www.fool.com - December 11 at 9:42 AM
Unheard of responses to bluebird CAR-T therapy seen in myeloma study - Reuters'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study - Reuters
www.reuters.com - December 10 at 5:13 PM
Celgene (CELG) Upgraded at Atlantic SecuritiesCelgene (CELG) Upgraded at Atlantic Securities
www.americanbankingnews.com - December 8 at 10:28 PM
Celgene: Easily The Best Valued Big Pharma Company - Seeking AlphaCelgene: Easily The Best Valued Big Pharma Company - Seeking Alpha
seekingalpha.com - December 8 at 9:51 AM
Morning Movers: United, Celgene Climb; Ciena SlipsMorning Movers: United, Celgene Climb; Ciena Slips
finance.yahoo.com - December 8 at 9:51 AM
Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be ReportedLong-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported
finance.yahoo.com - December 7 at 5:22 PM
CKPT: A Mad Scramble for Combination Therapy Makes Checkpoint a GemCKPT: A Mad Scramble for Combination Therapy Makes Checkpoint a Gem
finance.yahoo.com - December 7 at 5:22 PM
ETFs with exposure to Celgene Corp. : December 7, 2017ETFs with exposure to Celgene Corp. : December 7, 2017
finance.yahoo.com - December 7 at 5:22 PM
CKPT: A Smokin’ Opportunity in PD-L1 Therapy and BeyondCKPT: A Smokin’ Opportunity in PD-L1 Therapy and Beyond
finance.yahoo.com - December 6 at 5:02 PM
What Analysts Recommend for Pfizer in November 2017What Analysts Recommend for Pfizer in November 2017
finance.yahoo.com - December 5 at 10:34 AM
Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained CountriesCelgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries
finance.yahoo.com - December 5 at 10:34 AM
Sinking Industry Group Rank Keep Celgene (CELG) a SellSinking Industry Group Rank Keep Celgene (CELG) a Sell
investorplace.com - December 4 at 3:00 PM
First Week of July 2018 Options Trading For Celgene (CELG)First Week of July 2018 Options Trading For Celgene (CELG)
www.nasdaq.com - December 1 at 5:11 PM
Oversold Conditions For Celgene (CELG)Oversold Conditions For Celgene (CELG)
www.nasdaq.com - November 30 at 4:58 PM
Celgenes softer guidance for 2020 pressures shares, down 2%Celgene's softer guidance for 2020 pressures shares, down 2%
seekingalpha.com - November 30 at 4:31 PM
Lightning Round: Jim Cramer Shares His Thoughts On Celgene, ON Semiconductor, And MoreLightning Round: Jim Cramer Shares His Thoughts On Celgene, ON Semiconductor, And More
www.benzinga.com - November 30 at 10:21 AM
Cramer's lightning round: Don't be greedy, buy Celgene hereCramer's lightning round: Don't be greedy, buy Celgene here
finance.yahoo.com - November 29 at 5:20 PM
Cramers lightning round: Dont be greedy, buy Celgene hereCramer's lightning round: Don't be greedy, buy Celgene here
finance.yahoo.com - November 29 at 9:59 AM
What Should Investors Know About The Future Of Celgene Corporation’s (CELG) Business?What Should Investors Know About The Future Of Celgene Corporation’s (CELG) Business?
finance.yahoo.com - November 29 at 9:59 AM
Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - November 28 at 8:24 AM
Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report?Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report?
finance.yahoo.com - November 28 at 8:24 AM
Celgene Corporation (CELG) Short Interest Up 37.9% in NovemberCelgene Corporation (CELG) Short Interest Up 37.9% in November
www.americanbankingnews.com - November 27 at 11:32 PM
Celgene Corporation (CELG) Expected to Announce Quarterly Sales of $3.46 BillionCelgene Corporation (CELG) Expected to Announce Quarterly Sales of $3.46 Billion
www.americanbankingnews.com - November 27 at 6:40 PM
ETFs with exposure to Celgene Corp. : November 27, 2017ETFs with exposure to Celgene Corp. : November 27, 2017
finance.yahoo.com - November 27 at 6:20 PM
Zacks: Analysts Anticipate Celgene Corporation (CELG) to Announce $1.91 Earnings Per ShareZacks: Analysts Anticipate Celgene Corporation (CELG) to Announce $1.91 Earnings Per Share
www.americanbankingnews.com - November 25 at 1:14 PM
CAR-T Therapy Space 2017 Progress ReportCAR-T Therapy Space 2017 Progress Report
finance.yahoo.com - November 24 at 3:51 PM
Celgene Corporation (CELG) Receives Consensus Recommendation of "Buy" from BrokeragesCelgene Corporation (CELG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 23 at 8:24 PM
Celgene Corporation (CELG) Stock Rating Reaffirmed by CannCelgene Corporation (CELG) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - November 23 at 7:20 PM
Celgene (CELG) Announces Results from 282 Abstracts Including its Therapies and Pipeline Compounds to Be Presented at ASHCelgene (CELG) Announces Results from 282 Abstracts Including its Therapies and Pipeline Compounds to Be Presented at ASH
www.streetinsider.com - November 22 at 10:49 PM
Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... - Business Wire (press release)Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American ... - Business Wire (press release)
www.businesswire.com - November 22 at 5:49 PM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.